"Androxal presents several potential advantages including oral dosing, fewer side effects, and preservation of fertility," Bank of America says, initiating Repros Therapeutics (RPRX +3.3%) at Buy with a $25 price target. Analyst Steve Byrne sees peak 2022 sales of $450M for the low testosterone treatment, although there are potential risk factors including "a remaining phase 3 read-out" and the company's lack of "commercialization experience."
"Androxal presents several potential advantages including oral dosing, fewer side effects, and...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs